Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.
Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of squamous cell carcinoma, lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market/request-sample.html
Key Market Insights
§ Presently, more than 85 product candidates are being investigated for the treatment of metastatic or advanced squamous NSCLC patients, across different phases of development
§ Majority of the therapies are being evaluated in early stages for delivery via a number of administration routes, either as monotherapies or in combination with other drug products
§ Over 55 companies, including a mix of small players and veterans in the pharma industry, are engaged in the development of squamous NSCLC therapies
§ In pursuit of gaining a competitive edge, firms based in North America are actively investing, in terms of both resources and capital, to conduct R&D of squamous NSCLC targeting therapies
§ Over the past five years, the number of clinical studies have increased considerably across the world; most of the trials are active and primarily based in North America
§ There has been a rise in partnership activity reported within this domain, in recent years; most of the deals were inked for product development and commercialization of biologics
§ A number of scientists from renowned universities, who are presently involved in the clinical development efforts in this field of research emerged as key opinion leaders
§ The current market size is estimated to be USD 1.4 billion; this value is projected to reach USD 2.8 billion in 2026; monoclonal antibodies are expected to contribute to a significant share of the total revenues
§ The overall market opportunity for squamous NSCLC targeting therapies is likely to be distributed across different types of therapies, routes of administration and key geographical regions
The squamous non-small cell lung cancer market is projected to grow at a CAGR of 10.8% till 2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and growing demand for targeted and personalized therapeutic modalities. Biologics currently capture a significant market share, with the maximum revenue generation potential being associated with monoclonal antibodies; this trend is unlikely to change in the foreseen future.
For more information, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html
Table of Contents
1. Background
2. Executive Summary
3. Current Market Landscape
3.1. Market Landscape of Squamous NSCLC Drugs
3.2. Market Landscape of Squamous NSCLC Drug
Developers
4. Product Portfolio Competitiveness
4.1. Analysis by Geography
5. Key Market Insights
5.1. Clinical Trial Analysis
5.2. Partnerships and Collaborations
5.3. KOL Analysis
6. Market Forecast
6.1. Market Share by Type of Molecule / Drug Class
6.2. Market Share by Type of Therapy
6.3. Market Share by Route of Administration
6.4. Market Share by Geography
7. Drug Profiles
7.1. Afatinib
7.2. Pembrolizumab
7.3. Cadi 05
7.4. Nivolumab
7.5. Necitumumab
7.6. Tislelizumab
7.7. Camrelizumab
7.8. Canakinumab
7.9. Serplulimab
7.10. Ipilimumab
7.11. KN046
7.12. Cemiplimab
7.13. Niraparib
7.14. Penpulimab
7.15. Retifanlimab
7.16. SCT-I10A
7.17. Sintilimab
7.18. Atezolizumab
7.19. Toripalimab
7.20. Zimberelimab
7.21. AZD4547
7.22. Palbociclib
8. Appendix 1: Tabulated Data
9. Appendix 2: List Of Companies And Organizations
For additional details, please visit
https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
